Regorafenib Approved for Hepatocellular Carcinoma

Share this content:
Regorafenib Approved for Hepatocellular Carcinoma
Regorafenib Approved for Hepatocellular Carcinoma

THURSDAY, April 27, 2017 (HealthDay News) -- U.S. Food and Drug Administration approval of the kinase inhibitor regorafenib (Stivarga) has been expanded to include hepatocellular carcinoma, the agency said Thursday in a news release.

Regorafenib is the first drug approved to treat hepatocellular carcinoma in nearly a decade, the FDA said. Regorafenib is already FDA-approved to treat colorectal cancer and gastrointestinal stromal tumors, the agency said. The drug was approved for hepatocellular carcinoma patients treated previously with sorafenib.

Regorafenib's effectiveness for treating hepatocellular carcinoma was evaluated in a randomized trial of 573 people whose tumors had progressed despite treatment with sorafenib. The most common adverse events included gastrointestinal and abdominal pain, skin reactions, fatigue, diarrhea, loss of appetite, hypertension, and infection. More serious adverse events included hepatotoxicity, hemorrhage, gastrointestinal perforation or fistula, and cardiac ischemia and infarction.

Women who are pregnant or breastfeeding should not take regorafenib, the FDA said. And patients of both genders of child-bearing age who take the drug should use contraception, the agency added.

Approval of Stivarga was granted to Bayer HealthCare Pharmaceuticals, based in Whippany, New Jersey.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

SAMHSA: Youth Binge Drinking Rates Down in the United States

SAMHSA: Youth Binge Drinking Rates Down in the ...

But one in seven still consumed excess alcohol at least once in past month, study finds

Carpal Tunnel Up With Increased Electronic Device Use

Carpal Tunnel Up With Increased Electronic Device Use

Especially for those who spend more than five hours a day on their devices, researchers say

Guided Approach to Exercise May Help Chronic Fatigue Patients

Guided Approach to Exercise May Help Chronic Fatigue ...

Guided self-help approach to graded exercise program safe, reduces fatigue

is free, fast, and customized just for you!

Already a member?

Sign In Now »